8-K
0000728387false00007283872025-12-012025-12-01

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 01, 2025

 

 

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-33407

41-1458152

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

c/o Perspective Therapeutics, Inc.

2401 Elliott Avenue

Suite 320

 

Seattle, Washington

 

98121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

CATX

 

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01 Other Events.

On December 1, 2025, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Corporate Presentation.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PERSPECTIVE THERAPEUTICS, INC.

 

 

 

 

Date:

December 1, 2025

By:

/s/ Joel Sendek

 

 

 

Joel Sendek
Chief Financial Officer

 

Slide 1

Corporate Presentation

Slide 2

 

Slide 3

Developing the next generation of targeted therapies

Slide 4

Higher potency payloads with cancer-specific targeting

Slide 5

 

Slide 6

Upcoming data milestones

Slide 7

Radiopharmaceutical therapy poised to revolutionize oncology treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

Slide 8

 

Slide 9

Perspective’s Innovative Platform

Slide 10

Perspective’s radiopharmaceutical platform optimized for a broader therapeutic window

Slide 11

Perspective’s proprietary chelator has been optimized for lead-based RPTs

Slide 12

 

Slide 13

 

Slide 14

Proposed mechanism of action for 212Pb

Slide 15

Rationale for synergy with immune checkpoint inhibitors

Slide 16

 

Slide 17

Supply Chain and Manufacturing Infrastructure

Slide 18

On-demand order fulfillment at regional sites to deliver finished products

Slide 19

 

Slide 20

Neuroendocrine Tumors: VMT-⍺-NET

Slide 21

 

Slide 22

 

Slide 23

 

Slide 24

Trial design: [212Pb]VMT-⍺-NET Phase 1/2a for PRRT naïve neuroendocrine tumors

Slide 25

Compelling anti-tumor activity

Slide 26

Durable disease control across all doses

Slide 27

Signal of sustained anti-tumor activity

Slide 28

Best-in-class safety profile1

Slide 29

Select adverse events of special interest

Slide 30

Mild and generally transient blood creatinine increase

Slide 31

[212Pb]VMT-α-NET was well-tolerated and demonstrated compelling anti-tumor activity

Slide 32

Melanoma Program: VMT01/02

Slide 33

 

Slide 34

 

Slide 35

 

Slide 36

 

Slide 37

Trial design: [212Pb]VMT01 Phase 1/2a for metastatic melanoma

Slide 38

 

Slide 39

Treatment emergent adverse events (all grades, occurring in ≥ 2 patients)

Slide 40

 

Slide 41

 

Slide 42

 

Slide 43

 

Slide 44

 

Slide 45

PSV359 is active against FAP-α expression on tumor and on stroma

Slide 46

 

Slide 47

 

Slide 48

Trial design: [212Pb]PSV359 Phase 1/2a trial

Slide 49

 

Slide 50

General Corporate Information

Slide 51

 

Slide 52

 

Slide 53

 

Slide 54

 

Slide 55

Abbreviations

Slide 56

APPENDIX

Slide 57

 

Slide 58

NETs trials

Slide 59

Potential for differentiated profile based on molecular design

Slide 60

Durable disease control across all doses

Slide 61

Refractory metastatic melanoma trials

Slide 62

Daily production at regional sites ensures supply of ready-to-administer product

Slide 63

 

Slide 64

 

Slide 65

 

Slide 66

 

Slide 67

 

Slide 68

Perspective’s pre-targeting platform